This is the first time scientists have reported a biological mechanism to explain why some marijuana users have reported beneficial effects from cannabis on intestine inflammation conditions such as ulcerative colitis and Crohn's disease.
The media is claiming that long-term cannabis use could result in damage to the human brain based on findings from a research study that used neither cannabis or humans.
The first voluntary product recall in California was initiated by the vape cartridge manufacturer, The Bloom Brand, on July 25 and the second by Lowell Herb Co. concerning a batch of their pre-rolled cannabis cigarettes.
Mice who received a combination of CBD and chemotherapy survived nearly three times as long as the mice given the placebo, and around twice as long as the mice given CBD or chemotherapy alone.
What's most transformative about this drug approval is that this is the first time the FDA - the governmental arbiter of safe and effective medicine in the United States - has approved any substance derived from the cannabis plant.
The American Osteopathic Association supports the reclassification of cannabis as a Schedule II Drug to facilitate advancement in clinical, public health, patient safety and health policy research, according to a resolution approved by the AOA House of Delegates.
Mounting evidence suggests that the inflammatory processes in the brain contribute to the pathologies of Parkinson's, Alzheimer's and HIV-Associated Neurocognitive Disorders.
The changes concern the reclassification of cannabis to make it a schedule 2 drug, allowing it to be prescribed by medical professionals and possessed lawfully by anybody with a valid medical prescription.